OUR PERSPECTIVE

Shortcomings of existing therapies

Current standard of care treatments are ineffective for millions worldwide.

Limited Efficacy

Slow onset – Up to 3 months for SSRIs to take full effect
Inadequate response – ~33% of patients with depression become treatment-resistant
Ineffective care– ~60-70% of patients with depression are likely to relapse with current care
High relapse rate – ~75% of patients undergoing OUD therapy experience relapse within 1 year

Side Effects

Addiction – Long-term benzodiazepine use is associated with development of drug dependence
Sexual dysfunction – Side effects of SSRIs include sexual dysfunction
Weight gain – Patients on SSRIs can experience weight gain
Sleep – SSRIs interfere with sleep architecture, potentially complicating the sleep of depressed patients

Our unique approach

microscope icon

Compounds with prior evidence in humans

To minimize development risk, we focus on compounds that have previously been used in humans and have established safety profiles.

https://www.atai.life/wp-content/uploads/2020/11/home-1b.png
data icon

Enabling platform technologies

Leveraging proprietary technology to accelerate drug discovery, reposition existing molecules with big data approaches, and improve patient outcomes with digital therapeutics.
https://www.atai.life/wp-content/uploads/2020/11/home-2b.png
platform-model icon

Decentralized drug development

In addition to funding, our evolving companies have access to our deep domain expertise and operational backbone.

https://www.atai.life/wp-content/uploads/2020/11/home-3b.png

Learn more about our approach

OUR MODEL
WHERE WE’RE HEADED

Our technologies drive efficient drug discovery and improved treatment outcomes.

Our unique model combines funding with operational expertise to develop innovative and impactful CNS therapeutics. 

OUR MODEL

News & Insights

JOIN THE ATAI #INSIGHTNETWORK

Sign up to receive the latest news on atai.

Email
submit